← Back to Clinical Trials
Recruiting NCT01840930

NCT01840930 Cohort of Children With Severe Cerebral Palsy

◆ AI Clinical Summary
Plain-language summary for patients
Clinical Trial Summary
NCT ID NCT01840930
Status Recruiting
Phase —
Sponsor Hospices Civils de Lyon
Condition Orthopedic Complications in Cerebral Palsy
Study Type OBSERVATIONAL
Enrollment 385 participants
Start Date 2009-09
Primary Completion 2030-12

Eligibility & Interventions

Sex All sexes
Min Age 2 Years
Max Age 10 Years
Study Type OBSERVATIONAL

Eligibility Fast-Check

Enter your details for a quick preliminary check. This does not replace medical advice.

What to Expect as a Participant

This is an observational study. You will not receive an experimental treatment; researchers will collect data based on your existing condition or standard treatment.

This trial targets 385 participants in total. It began in 2009-09 with a primary completion date of 2030-12.

⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.

Brief Summary

" Cohort CP " is a multicentre cohort study, initiated by the Hospices Civils de Lyon in September 2009. Population targeted are children with bilateral cerebral palsy, level GMFCS IV or V, aged from 2 to 10 years at inclusion. They are followed-up during 10 years, at the rhythm of 1 visit per year. At each visit are collected clinical, orthopaedic, radiological and environmental data. The primary objective is to establish the incidence of orthopaedic complications (scoliosis and hip joint) depending on patients' age. Secondary objectives are to describe the sequences over time of these complications and the related pain, to explore the impact of nutrition, surgery, asymmetric postures and environmental factors, and to describe the medical and rehabilitative follow-up of these patients. 385 patients are expected by the end of 2020. We expect of this long-term follow-up to gain tools that permit to improve patient's care and patient's quality of life, by putting in place preventing actions and adapted treatments related to their own pathologies.

Eligibility Criteria

Inclusion Criteria: * Children aged from 2 to 10 years at inclusion, * with bilateral cerebral palsy, * Grade IV or V of the GMFCS. * Affiliated with the French healthcare system. * Oral consent of the parents obtained. Exclusion Criteria: \- Progressive pathology.

Contact & Investigator

Central Contact

Isabelle POIROT, PhD

✉ isabelle.poirot@chu-lyon.fr

📞 4 78 86 16 64

Principal Investigator

Isabelle POIROT, PhD

PRINCIPAL INVESTIGATOR

Hospices Civils de Lyon - Hôpital Femme Mère Enfant

Frequently Asked Questions

Who can join the NCT01840930 clinical trial?

This trial is open to participants of all sexes, aged 2 Years or older, up to 10 Years, studying Orthopedic Complications in Cerebral Palsy. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.

Is NCT01840930 currently recruiting?

Yes, NCT01840930 is actively recruiting participants. Contact the research team at isabelle.poirot@chu-lyon.fr for enrollment information.

Where is the NCT01840930 trial being conducted?

This trial is being conducted at Bron, France.

Who is sponsoring the NCT01840930 clinical trial?

NCT01840930 is sponsored by Hospices Civils de Lyon. The principal investigator is Isabelle POIROT, PhD at Hospices Civils de Lyon - Hôpital Femme Mère Enfant. The trial plans to enroll 385 participants.

Related Trials

Related Intelligence Guides

In-depth guides covering this condition's trials, eligibility, and what to expect.

ClinicalMetric — Independent clinical trial intelligence platform. Not affiliated with NIH, ClinicalTrials.gov, the U.S. FDA, or any pharmaceutical company, hospital, or clinical research organization. Trial data is sourced from ClinicalTrials.gov for informational purposes only and does not constitute medical advice. Do not make any treatment, enrollment, or health decisions based solely on information found here — always consult a qualified healthcare professional. Full Disclaimer  ·  Last Reviewed: November 2026  ·  Data Methodology